Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107441 | 0.84 | TDP1 (0.42) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL1811038 | 0.76 | SLC22A6 (0.38) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| Formic Acid SCHEMBL20836208 | 0.75 | TDP1 (0.78) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL9213672 | 0.74 | TDP1 (0.59) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL10888018 | 0.74 | SLC22A6 (0.36) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL9911939 | 0.74 | TDP1 (0.59) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL17517216 | 0.74 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL22151 | 0.74 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL16925719 | 0.74 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA | |
| SCHEMBL165643 | 0.74 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663399-B1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | GC BIOPHARMA CORP. (KR) | 2021-08-05 | — | — | US | disclosed |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | GC BIOPHARMA CORP. (KR) | 2021-07-29 | — | — | US | disclosed |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3663399-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200140840-A1 | FACTOR IX VARIANTS AND METHODS OF USE THEREFOR | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190055534-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | OAKTREE FUND ADMINISTRATION, LLC | 2019-02-21 | — | — | US | disclosed |
| US-10160961-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-9796986-B2 | Serum-free stable transfection and production of recombinant human proteins in human cell lines | OCTAPHARMA AG (CH) | 2017-10-24 | — | — | US | disclosed |
| WO-2001064748-A1 | ANTIBODIES BINDING A GAMMA CARBOXYGLUTAMIC ACID DISPLAYING EPITOPE | PROTEASE AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001016166-A2 | POLYPEPTIDES, COMPRISING IL-6 LIGAND-BINDING RECEPTOR DOMAINS, AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0624199-B1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS INC (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5527692-A | COMPRISING ACTIVATED RECOMBINANT GLA-DOMAINLESS PROTHROMBIN, WHICH IS CLEAVABLE TO THROMBIN | ZYMOGENETICS, INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5502034-A | EXPRESSION OF THROMBIN PRECURSOR IN HOST CELL, TREATMENT OF BLEEDING DISORDERS | ZYMOGENETICS, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5476777-A | DNA construct directing expression of thrombin precursor, including transcriptional promoter, DNA segment encoding gla-domainless prothrombin, transcriptional terminator | ZYMOGENETICS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0624199-A1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS, INC. (US) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993013208-A1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5225537-A | METHODS FOR PRODUCING HYBRID PHOSPHOLIPID-BINDING PROTEINS | ZYMOGENETICS, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| WO-1991009953-A1 | METHODS FOR PRODUCING HYBRID PHOSPHOLIPID-BINDING PROTEINS | ZYMOGENETICS, INC. (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160961-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | TDP1 982/4885SMN1; SMN2 1490/4885SLC22A6 1565/4885 |
| US-20190055534-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | F7, F13B, HABP2 | TDP1 999/4885SMN1; SMN2 1503/4885SLC22A6 1559/4885 |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | F13B, F9, F13A1 | TDP1 3648/4885SMN1; SMN2 1359/4885SLC22A6 1013/4885 |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | F9, F13B, F13A1 | TDP1 1805/4885SMN1; SMN2 2865/4885SLC22A6 3988/4885 |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | TDP1 999/4885SMN1; SMN2 1503/4885SLC22A6 1559/4885 |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | F9, F13B, F8 | TDP1 2133/4885SMN1; SMN2 2917/4885SLC22A6 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.